

Novonesis climate action position

Our People. Planet. Positive. ambition has four strategic agendas, one of which is to *Mitigate climate impact*.

We pioneer biosolutions that enable greenhouse gas (GHG) emission reductions across multiple industries, supporting the transition to a low-carbon society.

We are committed to ambitious actions to reach net-zero GHG emissions by 2050*.

We are committed to climate action by:

Enabling customers to reduce their climate footprint

- We deliver biosolutions that replace fossil-based ingredients and improve process efficiency, helping customers cut GHG emissions across production and use.
- We monitor the climate benefits delivered by key biosolutions and verify they outweigh the greenhouse gas emissions associated with the production of our full product portfolio.

Enhancing business resilience through climate adaptation

- We identify climate risks as part of our enterprise risk management framework, which identifies, assesses, and mitigates risks that may impact our ability to grow our business sustainably.
- We recognize that supply-demand driven by climate change could impact trade relationships, supply chains, operational costs, and strategic planning, and we have a series of mitigation actions such as reducing dependencies on critical and single-sourced raw materials.
- We expand our biosolutions portfolio to help customers adapt to changing climate and resource landscapes.

Enabling a low-carbon future through dialogue, awareness and advocacy

- We raise awareness of climate action and biosolutions on the global stage.
- We collaborate with stakeholders to demonstrate how biosolutions accelerate the green transition, create sustainable economic growth, and generate employment.
- We engage in global climate leadership, such as through our representation on the UN Global Compact Board of Trustees and the World Economic Forum's Climate Leaders Alliance.
- We conduct sustainability assessments to document the climate impact of our biosolutions and impact on customer product or process.
- We provide reliable science-based documentation on the climate impact of our biosolutions, helping inform customers, partners, and policymakers.

Enhancing transparency and accountability

- We report on climate performance, risks, opportunities, governance, and value chain engagement in our annual report and CDP Climate Change response.
- We strive to improve climate data quality and transparency across our operations and supply chain.
- We work with suppliers to strengthen data foundations and enable more accurate Scope 3 reporting.

Ensuring strong sustainability governance

- We integrate sustainability and climate change into Novonesis strategy, innovation, and external positioning, owned by Executive Leadership Team (ExLT).
- The Board of Directors oversees sustainability and our climate transition plan, reviews progress against it and assesses sustainability-linked remuneration policies annually.
- We evaluate the Board of Directors’ sustainability and climate change competencies when recruiting new members.
- We assess all existing biosolutions and innovation projects for alignment with the UN Sustainable Development Goals, including Affordable and Clean Energy (SDG 7) and Climate Action (SDG13).

Growing our business while lowering our emissions

- We are committed to achieving net-zero greenhouse gas emissions by 2050.
- We validate our climate targets through the Science Based Targets initiative (SBTi), ensuring alignment with the Paris Agreement and the ambition to limit global warming to 1.5°C.
- We have a decarbonization strategy.
- We implement optimization and energy efficiency projects to reduce our overall energy consumption, reusing energy where possible, and increasing our sourcing of renewable energy.
- We drive optimization of our production and supply chain to limit raw material and energy usage and its associated GHG emissions, especially in scope 3.
- We collaborate with our suppliers to identify and implement decarbonization opportunities.

*Our SBTi-validated net-zero targets

Novonesis commits to reach net-zero GHG emissions across the value chain by 2050 from a 2018 base year.

Near-Term Targets: Novonesis commits to: reduce absolute Scope 1 and 2 GHG emissions by 75% by 2030 from a 2018 base year; increase annual sourcing of renewable electricity from 37% in 2018 to 100% by 2025 and maintain 100% sourcing of renewable electricity through 2030; and reduce absolute Scope 3 GHG emissions from purchased goods and services, fuel and energy-related activities, upstream transportation and distribution, waste generated in operations, and business travel by 35% by 2030 from a 2018 base year.

Long-Term Targets: Novonesis commits to: reduce absolute Scope 1 and 2 GHG emissions by 90% by 2050 from a 2018 base year, and reduce absolute Scope 3 GHG emissions from purchased goods and services, fuel and energy-related activities, upstream transportation and distribution, waste generated in operations and business travel by 90% within the same time frame.

The target boundary includes biogenic emissions and removals associated with the use of bioenergy.

Responsible for the implementation of the Sustainability Commitment:

Chief Operating Officer, Chief Scientific Officer, and Executive Vice President of People and Stakeholder Relations

Version: January, 2026

Novonesis is leading the era of biosolutions.

By leveraging the power of microbiology with science, we transform the way the world produces, consumes and lives. In more than 30 industries around the world, our biosolutions are already creating value for thousands of customers and benefiting the planet. Our 11,000 people worldwide work closely with our partners and customers to transform business with biology. Let's better our world with biology.

The information provided herein is for general information purposes only. All information is provided in good faith. There is no warranty being extended and no liability whatsoever (including without limitation, any direct or indirect damages for lost profits or business interruption) is accepted as to its accuracy, completeness, correctness, non-infringement, merchantability, or fitness for a particular purpose. The product(s) may be covered by pending or issued patents, registered or unregistered trademarks, or similar intellectual property rights. Copyright © Novonesis Group, by ownership or license. All rights reserved.